The Metabolic Thread: supporting women's health at every stage

Nature recently ran a feature on perimenopause science, putting women's health on the front page of one of the world's most widely read scientific journals. 

The feature highlights that we struggle to treat perimenopause well because we don't yet fully understand it. Symptom patterns are inconsistent. Presentation varies enormously between women. The biology is more complex than a simple hormone drop would suggest. All of this is true.

But there's a vital lens the article largely passes over. And I believe it changes the picture considerably.

Oestrogen as a metabolic buffer

When I work with women in perimenopause, one of the first things I explain is that oestrogen isn't only a reproductive hormone. It has been acting, throughout a woman's adult life, as a metabolic buffer. It supports insulin sensitivity, regulates inflammatory responses, distributes fat away from the abdomen, modulates appetite signalling, and plays a role in circadian rhythm and brain function.

When oestrogen begins to decline, that buffer is gradually removed. What gets revealed is each woman's underlying metabolic health. If her blood sugar regulation has been under strain for years, the removal of oestrogen's protective effect will accelerate that strain. If she carries a high inflammatory load, chronic sleep disruption, or significant visceral fat, those patterns will be amplified rather than dampened. Perimenopause doesn't create these problems from nothing. It exposes them.

This is the metabolic thread I follow in clinical practice. By looking through this lens, we can start to see a unifying pattern in the data that Nature describes, one that moves us from 'inconsistent symptoms' toward a clearer physiological map.

Why symptoms vary so much between women

The Nature feature is right that symptom variation is poorly understood. Two women of the same age, with the same hormonal profile and even the same BMI, can have radically different experiences of perimenopause. One woman is debilitated by vasomotor symptoms and cognitive changes. Another barely notices the transition. Current research has limited tools for explaining why.

The metabolic lens offers at least a partial answer. Women arrive at perimenopause with different metabolic starting points: different levels of insulin sensitivity, different gut microbiome compositions, different muscle mass, different chronic inflammatory burdens, and different sleep quality accumulated across decades. These differences shape how severely the removal of oestrogen's protective effect is felt.

The variation between women isn't random. It reflects each woman's metabolic resilience going into the transition.

A study published in the Journal of Clinical Endocrinology and Metabolism in January 2026 found that higher insulin levels at age 47 predicted both earlier hot flash onset and longer hot flash duration. Critically, insulin remained a significant predictor even when BMI was controlled for, suggesting it operates through mechanisms distinct from body weight alone. That finding shifts the frame. If insulin sensitivity is an independent driver of vasomotor symptoms, then addressing metabolic health directly becomes a more specific lever than general lifestyle advice has previously implied.

This builds on earlier work from the SWAN cohort, a long-running observational study in the United States. Thurston and colleagues (2012, JCEM) found that women with frequent hot flashes had significantly higher insulin resistance, independent of body weight and hormone levels. That study's design means we can observe the association but not confirm causation. The pattern is consistent, and it has held up across populations.

Blood sugar, body composition, and brain fog

The cognitive symptoms of perimenopause are among the most distressing for the women I see: the brain fog, the word-finding difficulties, the sense that thinking has become slower and less reliable. They're also among the least discussed in the research.

Converging evidence suggests that metabolic dysfunction may contribute to neuroinflammation, which in turn may play a role in cognitive and mood changes during the transition. The mechanism is not yet firmly established, but the direction is consistent enough to take seriously in clinical practice.

What we do have clearer evidence on is postprandial glucose response. The ZOE PREDICT study (Bermingham et al., 2022, eBioMedicine) used continuous glucose monitoring in over 1,000 women and found that postmenopausal women had significantly worse postprandial glucose responses, including higher fasting glucose and HbA1c, compared with premenopausal women. This points to a measurable metabolic shift that sits alongside the hormonal one.

Body composition matters here too. Wright and colleagues (2024, Climacteric) found that more than 70% of women experience musculoskeletal symptoms during the menopause transition, and that pro-inflammatory markers including IL-6 and TNF-alpha rise as oestrogen declines. Muscle mass matters because muscle is metabolically active tissue. Reduced muscle mass, rising inflammatory markers, and increasing glycaemic variability are not three separate problems. In most women, they travel together.

A pointed question about CLIMATÈRE

The Nature article references the CLIMATÈRE study, a French cohort following more than 100,000 women from age 30, with a planned 20-year follow-up. I welcome that scale of investment in women's health research. We need it badly.

But I want to pose a question that I think the field has not yet answered satisfactorily: why isn't a study of that size specifically designed to investigate the impact of metabolic health on menopause, rather than the other way round? The metabolic conditions that shape a woman's perimenopause experience are being set 20 or 30 years before her periods begin to change. Insulin sensitivity in her 30s, her inflammatory burden in her 40s, her sleep architecture across her working life. These are the foundations that will determine how the transition lands.

We keep measuring what menopause does to metabolic health. We're less systematic about measuring what metabolic health does to the menopause.

On Pauline Maki's point

The Nature article quotes Pauline Maki, a neuroscientist at the University of Illinois Chicago: "We don't yet understand how treating menopause symptoms, regardless of whether it's hormonal or non-hormonal, benefits women or not."

That framing leaves women with nowhere to go. And many of them have been waiting long enough.

When I support a woman's metabolic health through nutrition, movement, and sleep quality, I am working with a lever that is measurable in real time. I can track insulin sensitivity improving. I can see glycaemic variability reducing on a continuous glucose monitor. I can observe changes in inflammatory markers and body composition over months. The benefit isn't theoretical, and the feedback loop doesn't require a 20-year cohort to see.

When women are told "we don't yet understand enough to know what helps," the implicit message is: wait. And many of them have been waiting for a long time already.

What this means for women right now

The Nature feature is a genuine contribution to a conversation that has been underfunded and underserved. I don't read it as pessimistic in intent. But the conclusion that "we don't understand perimenopause well enough" risks being heard as "there's not much we can do". This isn't true.

The metabolic lens doesn't close every gap in the science. But it offers something concrete, measurable, and accessible. A woman who understands that her blood sugar regulation, her inflammatory burden, and her sleep quality are all shaping how her perimenopause feels has somewhere to start. She has levers she can actually pull, with clinical support, before the research catches up.

That's where I spend my clinical time. In the consultation room, working through what each individual woman's metabolic picture looks like and what, specifically, she can do about it now. The symptoms were never the whole story. They're signals. And the question is whether we're listening carefully enough to what they're pointing to.

Dr Rebecca Hiscutt is a PhD Dietitian and Metabolic Health Specialist. Founder of The Metabolic Thread — supporting women's health at every stage. www.drrebeccahiscutt.com

References

Bermingham, K.M., et al. (2022). Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study. eBioMedicine, 85, 104303. https://doi.org/10.1016/j.ebiom.2022.104303

Thurston, R.C., et al. (2012). Vasomotor symptoms and insulin resistance in the Study of Women's Health Across the Nation. Journal of Clinical Endocrinology and Metabolism, 97(10), 3487–3494. https://doi.org/10.1210/jc.2012-1410

Wright, D., et al. (2024). Musculoskeletal symptoms and inflammation during the menopause transition. Climacteric. https://doi.org/10.1080/13697137.2024.2380363

Athar, F., Gregory, S., Houston, E.J., & Templeman, N.M. (2026). [Title to be confirmed]. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf699 [PMID 40963750]

Nature feature referenced: "The missing pieces of menopause science," Nature, 7 March 2026. https://doi.org/10.1038/d41586-026-00692-9